Skip to main content
. Author manuscript; available in PMC: 2015 Apr 13.
Published in final edited form as: Melanoma Res. 2014 Jun;24(3):207–218. doi: 10.1097/CMR.0000000000000060

Fig. 5.

Fig. 5

Canertinib can overcome vemurafenib resistance in A375-VR cells. (a) A375 BRAF mutant cells were treated with increasing concentrations of vemurafenib to generate a resistant cell line, A375-VR. A375-VR and A375 parental cells were treated with increasing concentrations of vemurafenib for 3 days and analyzed by MTT assay. (b) Vemurafenib treated cells were treated with or without 5 μmol/l canertinib for 3 days and analyzed by MTT. Percentage growth inhibition was calculated for each treatment group.